Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#4561 Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,

#4553 The efficacy of “rechallenge” peptide receptor radionuclide therapy (PRRT) may be inferior to that of the initial PRRT, while the safety profile remains comparable

Introduction: Data on efficacy and adverse events of re-challenge PRRT (re-PRRT) for patients with gastrointestinal neuroendocrine tumours (GI-NETs) are limited.

Conference:

Presenting Author: Heinrich M

Authors: Heinrich M, Lutz F, Alwers S, Däubler C, Buck A,

Keywords: gastrointestinal neuroendocrine tumour, somatostatin receptor directed PET, laboratory parameters, Progression-free survival,

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,